rad001

Key facts

Mechanism of action

FK506-binding protein 1A inhibitor

Primary target: Peptidyl-prolyl cis-trans isomerase FKBP1A

Approval history

1. EVEROLIMUS Phase 3 · Novartis India · Refractory seizures associated with tuberous sclerosis compl
2. Everolimus Phase 3 · Novartis India · Advanced NET of GI Origin
3. RAD001 Phase 3 · Novartis India · Tuberous Sclerosis Complex-associated Refractory Seizures
4. Capecitabine Phase 2 · Novartis India · Breast Cancer
5. RAD001 Phase 2 · Ultragenyx UK · PTEN Gene Mutation

1. everolimus Antineoplastic and immunomodulating agents (L01)
2. sirolimus Antineoplastic and immunomodulating agents (L04)
3. tacrolimus Dermatologicals (D11)
4. pimecrolimus FK506-binding protein 1A inhibitor
5. temsirolimus Antineoplastic and immunomodulating agents (L01)
6. fk506 FK506-binding protein 1A inhibitor

Frequently asked questions